Last reviewed · How we verify
MB-CART2019.1 Dose level 2
At a glance
| Generic name | MB-CART2019.1 Dose level 2 |
|---|---|
| Also known as | CD2019-targeting CAR T cells, Anti-CD2019 CAR T cells |
| Sponsor | Miltenyi Biomedicine GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-CART2019.1 Dose level 2 CI brief — competitive landscape report
- MB-CART2019.1 Dose level 2 updates RSS · CI watch RSS
- Miltenyi Biomedicine GmbH portfolio CI